Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Innate and Adaptive Immunity in Parkinson Disease

ABSTRACT: Innate and Adaptive Immunity in Parkinson Disease

PROVIDER: PRJNA646549 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Innate and Adaptive Immunity in Parkinson Disease

Project description:Innate and Adaptive Immunity in Parkinson Disease

| PRJNA646548 | ENA

Adaptive and innate immune responses in MAC lung disease

Project description:Adaptive and innate immune responses in MAC lung disease

| PRJNA819939 | ENA

Gene Transcription Profile of Local Innate and Adaptive Immunity during Early Phase of IBV Infection

Project description:To understand the mechanistic basis of local innate and adaptive immunity against infectious bronchitis virus (IBV) at the molecular level, we examined the gene transcription profile of tracheal epithelial layers at 3 days after infection of chickens with an attenuated IBV-Massachusetts strain. Keywords: Disease State Analysis, Early mucosal immune response, FHCRC 13k chicken array

2006-11-03 | GSE6211 | GEO

PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer

Project description:PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer

| PRJNA1451829 | ENA

Parkinson Disease Frontal Cortex ncRNA Profiling

Project description:Parkinson Disease Frontal Cortex ncRNA Profiling

| PRJNA659521 | ENA

Parkinson Disease Frontal Cortex Transcriptomic analysis

Project description:Parkinson Disease Frontal Cortex Transcriptomic analysis

| PRJNA659523 | ENA

Adaptive and innate immune responses in MAC lung disease

Project description:Immunological mechanisms of susceptibility to NTM disease are poorly understood. We evaluated innate and antigen-specific adaptive immune responses to Mycobacterium avium complex in individuals with MAC lung disease. We investigated the gene expression changes induced in PBMCs by polyclonal stimulation (anti-CD3, anti-CD28), Mav and Mtb lysates and a peptide pool (MTB300) in individuals with MAC lung disease (MACDZ), and healthy controls (IGRA+ and IGRA-).

2022-09-23 | GSE199403 | GEO

Empowering macrophage to bridge innate and adaptive antitumor immunity through dual targeting of PCSK9 and innate immune checkpoint

Project description:Macrophage-directed immunotherapy has emerged as a promising strategy to eliminate tumors by unleashing phagocytosis, exemplified by blockade of the CD47-SIRPα “don’t eat me” axis. However, despite robust enhancement of phagocytosis, such approaches often fail to generate durable antitumor immunity in solid tumors, highlighting a critical disconnect between innate immune activation and effective T cell responses. Here, we identify PCSK9 as an adaptive resistance factor induced by macrophage immune checkpoint blockade. Tumor-derived PCSK9 promotes lysosomal degradation of MHC-I in macrophages, thereby impairing antigen cross-presentation and limiting CD8⁺ T cell priming. This previously unrecognized mechanism reveals how phagocytosis-targeted therapies can paradoxically suppress adaptive immunity. To overcome this resistance, we engineered bispecific fusion proteins that concurrently target the CD47-SIRPα phagocytosis checkpoint and the PCSK9–MHC-I antigen presentation axis, among which SIRPαD1-αPCSK9 emerged as the optimal format. Dual targeting synergistically enhances macrophage phagocytosis, preserves antigen cross-presentation capacity, and reprograms the tumor microenvironment toward an immunostimulatory state. Consequently, SIRPαD1-αPCSK9 elicits robust activation of both innate and adaptive antitumor immunity, leading to potent tumor control with improved safety. These findings uncover a novel mechanism of resistance to macrophage-centered immunotherapy and establish a rational dual-targeting strategy that bridges phagocytosis and T cell activation, offering a new paradigm for macrophage-driven cancer immunotherapy.

2026-06-17 | GSE335282 | GEO

Targeting Piezo1 Unleashes Innate Immunity Against Cancer and Infectious Disease

Project description:Targeting Piezo1 Unleashes Innate Immunity Against Cancer and Infectious Disease

| PRJNA649429 | ENA

OX40 mediates crosstalk between innate and adaptive immunity and promotes nonalcoholic steatohepatitis development

Project description:OX40 mediates crosstalk between innate and adaptive immunity and promotes nonalcoholic steatohepatitis development

| PRJNA415058 | ENA